Noboru Yamamoto
Runs Japan's largest first-in-human oncology unit, where many Daiichi Sankyo DXd ADCs were first given to patients.
Noboru Yamamoto leads early-phase drug development at the National Cancer Center Hospital, including first-in-human studies of trastuzumab deruxtecan, datopotamab deruxtecan, and other antibody-drug conjugates and targeted agents.
Pages like this
not linked directly; found by shared links- PersonToshihiko Doi
Shares Daiichi Sankyo, National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonKan Yonemori
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonBob T. Li
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- TermTetrapeptide GGFG (maleimide-GGFG-aminomethyl)
Shares Datopotamab deruxtecan, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- IdeaContinuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PairingCaution: DXd ADC + agents with pneumonitis risk
- InstitutionPharmaceuticals and Medical Devices Agency
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).